By admin | Published:
December 15, 2007
Jack Cuzick
JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged anastrozole, breast, cancer, inhibitor, inhibitors, iphone, london, medicine, podcast, podcasting, prevention, tamoxifen, test, thorne, trial |
By admin | Published:
December 15, 2007
Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details from Jose Baselga of Vall d’Hebron Hospital in Barcelona.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged breast, breast-cancer, cancer, drug, drugs, experimental arm, hospital barcelona, investigation, mp3, Oncology, podcast, podcasting, therapies, therapy, thorne, trial |
By admin | Published:
December 14, 2007
Margaret Foti
MARGARET FOTI, American Association for Cancer Research, Philadelphia
The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College of Medicine, and the American Association for Cancer Research. Peter Goodwin found out more on this new collaboration from Margaret Foti, CEO of the American Association for Cancer Research in Philadelphia.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in News | Tagged aacr, antonio breast cancer symposium, baylor college of medicine, breast cancer symposium, breast-cancer, cancer research, cancer therapy, college of medicine, foti, health science center, iphone, margeret, Oncology, peter goodwin, san antonio breast, san antonio breast cancer, san antonio breast cancer symposium, texas health science, texas health science center, university of texas health science center |
By admin | Published:
December 14, 2007
Stephen Jones
STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged breast cancer survival, breast-cancer, cyclophosphamide, docetaxel, doxorubicin, iphone, Oncology, oncology research, stephen jones, survival advantage, survival benefit, taxane, thorne, us oncology |
By admin | Published:
December 11, 2007
Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy approach – from Christian Geisler of Rigshospitalet in Copenhagen.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
December 10, 2007
Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged cancer, chemotherapy, hematologic, leukemia, patient, podcast, podcasting, presented, refractory, report, reports, trial |
By admin | Published:
December 10, 2007
Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged cancer, dasatinib, imatinib, News, patient, podcast, podcasting, report, reports, therapies, therapy |
By admin | Published:
December 10, 2007
Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged agent, ash, myelodysplastic, News, patient, podcast, podcasting, presented, report, reports, risk, study, syndrome |
By admin | Published:
December 10, 2007
Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Oncology | Tagged acute, cancer, leukemia, myeloid, News, patient, podcast, podcasting, report, reports, trial |
By admin | Published:
December 9, 2007
Terry Gernsheimer
TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Medicine | Tagged agent, drug, drugs, hematologic, investigation, medical, medication, News, patient, placebo, podcast, podcasting, study, trial |
By admin | Published:
December 9, 2007
Zakari Aliyu
REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with the disease. But a new study has shown that no one is using the standard therapy hydroxyurea to treat it. Derek Thorne got more from Zakari Aliyu of Howard University in Washington DC.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
Anton Hagenbeek
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.